Johnson & Johnson Vision (Acuvue)

What they make

2 inputs Johnson & Johnson Vision (Acuvue) supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

1 facility

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Did you know2022

  In 2022, the FDA approved Acuvue Theravision with Ketotifen — the world's first drug-eluting contact lens — as a prescription medical device. The lens releases ketotifen (an antihistamine/mast-cell stabilizer) continuously throughout the day, treating allergic conjunctivitis without eye drops. This makes JNJ Vision simultaneously a contact lens manufacturer and a drug delivery device company — blurring the boundary between the ophthalmic pharmaceutical and medical device supply chains. Future drug-eluting lenses in development include prostaglandin analogs for glaucoma treatment.

  U.S. Food and Drug Administration ↗

• Concentration2024

  The contact lens — a sterile medical device worn against the eye by roughly 150 million people daily — comes from one of the tightest oligopolies in consumer health. Johnson & Johnson Vision (Acuvue) is the world's largest maker, and together with Alcon, CooperVision and Bausch + Lomb, just four companies produce essentially all of the world's soft contact lenses. And Acuvue is itself only a small corner of Johnson & Johnson, one of the largest healthcare companies on Earth (pharmaceuticals and medical devices). So a daily disposable lens that feels like a commodity is actually a precision, FDA-regulated medical product made by a four-firm club, with one of the four being an arm of a healthcare giant. The barriers are real: contact lenses require sterile, high-speed manufacturing of oxygen-permeable silicone-hydrogel polymers to exacting optical and safety standards, qualified through medical-device regulation — which is exactly why the field never fragmented and remains controlled by a handful of makers worldwide.

  Johnson & Johnson Vision ↗

• Substitution2024

  The contact lens is quietly turning from a vision-correction commodity into a therapeutic platform, and the industry's competition is shifting with it. The biggest driver is myopia: childhood nearsightedness is surging worldwide (especially in East Asia), and specially designed contact lenses (and related optical treatments) can measurably slow its progression — so J&J's Acuvue and its rivals are racing to develop and sell myopia-management lenses, reframing a cosmetic/optical product as a public-health intervention for kids' eye development. Beyond that, the field is pushing toward smart and drug-eluting lenses — contacts that release medication into the eye or sense biomarkers. So the same precision silicone-hydrogel manufacturing that makes a daily disposable is being repointed at controlling disease and delivering drugs. It's another example from this radar of a mature consumer product being elevated into medicine, with the incumbent makers leveraging their materials and regulatory expertise to capture the higher-value, fast-growing therapeutic frontier rather than competing only on price for a basic lens. [verify: Myopia-management lenses surge real; J&J Acuvue + drug-eluting frontier well-documented]

  Johnson & Johnson Vision ↗

• Origin2024

  J&J Vision Care traces its origins to 1981, when Johnson & Johnson acquired Vistakon, a small Jacksonville, Florida startup that had patented the concept of disposable contact lenses. J&J commercialized the idea as the first daily-disposable contact lens (1-Day Acuvue, 1994) — one of the most commercially successful product launches in consumer healthcare history. The daily-disposable format, which J&J invented from scratch, now accounts for roughly 60% of global contact lens revenue. Vistakon's founder, Jim Nealis, sold the company to J&J for a few million dollars; by 2023 the business generates ~B/year in revenue.

  Johnson & Johnson Vision ↗